Beats Have Been the Rule, but Follow-Through Hasn't
Charles River Laboratories (CRL) has gone 8 for 8 on earnings beats over the last eight reported quarters, a 100% beat rate, with an average earnings surprise of 10.2%. That is a strong headline: every quarterly report since at least August 2025 has cleared the published consensus. The numbers are consistent even up close. On August 6, 2025, CRL reported actual EPS of $3.12 versus an estimate of $2.50, a 24.8% surprise. On November 5, 2025, actual EPS was $2.43 against $2.32, a 4.7% surprise. On February 18, 2026, actual EPS was $2.39 versus $2.33, a 2.6% surprise. The most recent quarter, May 7, 2026, posted actual EPS of $2.06 against an estimate of $1.96, a 5.1% surprise.
Yet the same period shows no reliable upward drift after these beats. The average 5-day price move in the five trading days after earnings across those eight quarters is -0.25%, classified as “flat.” The May 7, 2026 release is the cleanest example of the disconnect: a 5.1% EPS beat produced a -2.23% next-day move and a -12.42% drop over the following five sessions. For a reader who assumes “beat = pop and hold,” CRL’s track record is a useful counterexample. The earnings result measures quarterly execution; the stock’s multi-day path measures positioning, guidance language, sector flows, and how much of the beat was already discounted.
What a Disciplined Trader Watches
Because CRL’s post-earnings drift has averaged -0.25% despite eight consecutive EPS beats, the disciplined trader separates the result from the reaction. The first watch item is the 5-day path, not just the opening print. The May 2026 quarter sold off after a beat; the February 2026 quarter rallied 3.95% the next day and 6.05% over five days. There is no single-template outcome, so waiting for direction to develop after the headline can be more productive than chasing the gap.
The second watch item is sector context. CRL sits in Healthcare/Medical – Diagnostics & Research, a group that can move on biotech funding trends, clinic volumes, and broader risk appetite. With the RSI at 56.9, the stock is neither overbought nor oversold, meaning the post-earnings move is more likely to be driven by the report and guidance than by a mean-reversion setup. The third watch item is price structure: the 50-day EMA at $210.94 sits well below the current price of $230.90, so any post-announcement liquidation could test that zone if participants think the beat is fully priced.
For a deeper dive into CRL’s institutional rating mix, recent price-target revisions, and sector-relative positioning, see the full institutional verdict on the platform.
Frequently Asked Questions
What is CRL's earnings beat rate over the last 8 quarters?
How did CRL stock react after its most recent earnings report on May 7, 2026?
On May 7, 2026, CRL reported actual EPS of $2.06 versus an estimate of $1.96, a 5.1% beat. The stock still fell 2.23% the next day and declined 12.42% over the following five trading sessions.
When is CRL's next scheduled earnings report and what is the consensus estimate?
CRL is scheduled to report on August 5, 2026, before the market open, with a consensus EPS estimate of $2.74.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-05-07 | $2.06 | $1.96 | +5.1% | -2.23% | -12.42% |
| 2026-02-18 | $2.39 | $2.33 | +2.6% | +3.95% | +6.05% |
| 2025-11-05 | $2.43 | $2.32 | +4.7% | +1.9% | +2.27% |
| 2025-08-06 | $3.12 | $2.5 | +24.8% | -0.37% | +3.11% |
| 2025-05-07 | $2.34 | $2.06 | +13.6% | - | - |
| 2025-02-19 | $2.66 | $2.5 | +6.4% | - | - |
Previous CRL editions
Get the institutional verdict on CRL
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CRL verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.